In a new report published by the Brookings Institution, Matthew Fiedler, Ph.D. ’13 , a fellow in economic studies at the USC-Brookings Schaeffer Initiative for Health Policy, and Zirui Song, M.D. ’10, Ph.D. ’12, assistant professor of health care policy in the Blavatnik Institute at Harvard Medical School, estimate national health care spending for COVID-19 care and… Read More: New studies are estimating spending on COVID-19 »
Author Randy Arthur Published June 10, 2020 Word count 1,182 Cannabidiol (CBD) is an oil of cannabis plant origin. Possible health benefits include reducing the pain and inflammation. It isn’t legal in all jurisdictions, however, so there could be some threats as well. The Food and Drug Administration (FDA) approved the therapeutic use of Epidiolex,… Read More: Everything you need to know about CBD oil »
As Biogen preps for its closely watched aducanumab FDA filing in Alzheimer’s disease, a patent threat for the company’s top-selling medicine is causing concern for one team of analysts. In a note to clients Tuesday, Bernstein analyst Ronny Gal and his team downgraded Biogen’s stock—from outperform to market-perform—based on the belief that Mylan will win… Read More: Heads up, Biogen. After digging into Tecfidera patent arguments, analyst predicts… »
WHO walks backs its claim that the spread of coronavirus by asymptomatic people is ‘very rare’ as Harvard scientists slam the organization for ‘creating confusion’ and say those with no symptoms ARE spreaders On Monday, the WHO said it’s very rare that asymptomatic people spread coronavirus and that they are not a ‘main driver’ of… Read More: Coronavirus: Asymptomatic people ARE spreading disease »